Why Early Device Decisions Matter: How Immunovant Accelerated Its Clinical Program

Delaying the device decision can look like a way to keep options open. In practice, late autoinjector integration often brings PK bridging studies, added regulatory complexity, and slower movement through the clinical phases.

This case study follows an immunology developer that committed to a customized autoinjector at Phase IIb and moved from first-in-human to its first pivotal study in roughly 1.5 years, against a median of about 7.5 years for comparable programs. It examines how matched active and placebo devices, standardized documentation for IND submission, and a home-use trial design shaped that pace, and what it meant for downstream bridging work.

Explore the example to see how the early decision played out.